Extracellular ATP, hemopexin and vascular alterations in Preeclampsia*

Extracellular ATP, hemopexin and vascular alterations in Preeclampsia* - Hemopexin, ATP and preeclampsia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37052

Enrollment

295

Registered

2009-01-20

Start date

2011-02-15

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preeclampsia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Experiment 1: Pregnant women who have been diagnosed to be at increased risk for developing preeclampsia, i.e. women who have been diagnosed with pre-existent hypertension, diabetes mellitus, vasculitis, renal disease, autoimmune disease, malignancy, or women with preeclampsia in their previous pregnancy, women carrying twins. ;Experiment 2: Preeclamptic patients: * Preeclampsia defined by the ISSHP criteria (see onderzoeksprotocol) * Primigravid * Age: >/////

Exclusion criteria

Exclusion criteria: Experiment 1: pregnant women without an increased risk of developing preeclampsia;Experiment 2: Preeclamptic women: Diagnosis of pre-existent hypertension, diabetes mellitus, vasculitis, renal disease, autoimmune disease, malignancy, ;Healthy pregnant women: * Multiparity * Multiple pregnancy * Fetal growth retardation * Other pregnancy complications * Hypertension * Any known chronical illnesses * Age: 40 years * smoking;Control non-pregnant women: * Multiparity * Age: 40 years * Existence of any known diseases * smoking;pregnant women with preterm delivery Diagnosis of Treated pre-existent hypertension, diabetes mellitus, vasculitis, renal disease, autoimmune disease, malignancy, signs of infection

Design outcomes

Primary

Measure	Time frame
Experiment 1: Blood samples (10 ml heparinised and 10 ml EDTA) of 135 pregnant women at high risk for developing preeclampsia will be taken at weeks 10, 14, 18, 20 and 25, 30, 35 and 40 of pregnancy. We will measure plasma hemopexin activity and plasma ATP levels as well as various inflammatory parameters. Experiment 2: Blood samples (10 ml EDTA, 10 ml heparinised blood) will be taken from women diagnosed with preeclampsia (ISSHP criteria). We will measure activation of inflammatory cells and plasma concentrations of hemopexin, ATP, inflammatory parameters and other factors suggested to be involved in the pathogenesis of preeclampsia. In tissue biopsies we will measure endothelial cell activation and dysfunction.	—

Measure

Time frame

Experiment 1: Blood samples (10 ml heparinised and 10 ml EDTA) of 135 pregnant women at high risk for developing preeclampsia will be taken at weeks 10, 14, 18, 20 and 25, 30, 35 and 40 of pregnancy. We will measure plasma hemopexin activity and plasma ATP levels as well as various inflammatory parameters. Experiment 2: Blood samples (10 ml EDTA, 10 ml heparinised blood) will be taken from women diagnosed with preeclampsia (ISSHP criteria). We will measure activation of inflammatory cells and plasma concentrations of hemopexin, ATP, inflammatory parameters and other factors suggested to be involved in the pathogenesis of preeclampsia. In tissue biopsies we will measure endothelial cell activation and dysfunction.

—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results